{"entity":{"id":"nct06445972","kind":"trial","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","aka":[],"tldr":"A phase 1/2 trial of Ramucirumab and Sacituzumab tirumotecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) is a phase 1/2 interventional study registered as NCT06445972 by Merck Sharp & Dohme LLC, with 210 participants planned, started 2024-08-07 and due to reach its primary completion in 2028-05-09. Interventions recorded: Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications and HER3-DXd.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06445972","url":"https://clinicaltrials.gov/study/NCT06445972"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["ramucirumab","sacituzumab-tirumotecan"],"companies":["merck","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06445972","phase":"1/2","setting":"A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D","sponsor":"Merck Sharp & Dohme LLC","enrolled":210,"outcomes":[]},"route":"/trials/nct06445972/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}